{"hands_on_practices": [{"introduction": "Effective venous thromboembolism (VTE) prevention hinges on the appropriate administration of pharmacologic agents. A crucial aspect of this is tailoring the dose to the individual patient's physiology, particularly their renal function. This practice problem [@problem_id:5199490] challenges you to apply the widely used Cockcroft-Gault equation to estimate creatinine clearance in an elderly surgical patient. By performing this calculation, you will determine the correct dose of low molecular weight heparin (LMWH), reinforcing the vital clinical skill of adjusting renally-cleared medications to balance efficacy against the risk of bleeding.", "problem": "A general surgery inpatient requires pharmacologic prevention of venous thromboembolism (VTE) after a major open colectomy. She is a $76$-year-old female, weight $60$ kg, with a stable serum creatinine (SCr) of $1.6$ mg/dL, normal platelet count, no active bleeding, and no neuraxial catheter. She is expected to have limited mobility for at least $72$ hours. There are no contraindications to anticoagulation. \n\nUsing a standard adult drug-dosing estimator of creatinine clearance that is based on age, body weight, serum creatinine, and sex (the Cockcroft–Gault approach), first estimate her creatinine clearance in $\\mathrm{mL/min}$. Then, applying the pharmacokinetic principle that low molecular weight heparin (LMWH) is predominantly renally eliminated and requires dose reduction when creatinine clearance is less than $30$ $\\mathrm{mL/min}$, determine the appropriate once-daily enoxaparin prophylaxis dose. You may assume the institutional standard for normal renal function is enoxaparin $40$ mg subcutaneously every $24$ hours, with reduction to $30$ mg every $24$ hours when creatinine clearance is less than $30$ $\\mathrm{mL/min}$. \n\nProvide the final answer as the appropriate enoxaparin dose in mg for once-daily administration. Do not include units in the boxed answer. No rounding is required for the dose. Express the final dose in mg.", "solution": "The problem will be validated by first extracting the given information and then scrutinizing it against established criteria for scientific soundness, completeness, and objectivity.\n\n### Step 1: Extract Givens\n- Patient: $76$-year-old female\n- Weight: $60$ kg\n- Serum Creatinine (SCr): $1.6$ mg/dL\n- Indication: Pharmacologic prevention of venous thromboembolism (VTE) after major open colectomy.\n- Clinical status: Stable SCr, normal platelet count, no active bleeding, no neuraxial catheter, expected limited mobility for at least $72$ hours.\n- Contraindications to anticoagulation: None.\n- Required calculation method: Cockcroft-Gault approach for creatinine clearance ($\\text{CrCl}$).\n- Dosing rule for low molecular weight heparin (LMWH), specifically enoxaparin:\n    - Standard dose for normal renal function: $40$ mg subcutaneously every $24$ hours.\n    - Dose reduction required if $\\text{CrCl}  30$ $\\mathrm{mL/min}$.\n    - Reduced dose: $30$ mg every $24$ hours.\n- Goal: Determine the appropriate once-daily enoxaparin prophylaxis dose in mg.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity:\n- **Scientifically Grounded**: The problem is grounded in established principles of clinical pharmacology. The Cockcroft-Gault equation is a standard, albeit older, method for estimating creatinine clearance to guide drug dosing. The principle that LMWH is renally cleared and requires dose adjustment in renal impairment is a fundamental concept in therapeutics. The patient scenario and drug dosing regimen are clinically realistic.\n- **Well-Posed**: The problem provides all necessary data to perform the requested calculation and apply the given dosing rule. The instructions are clear, leading to a single, unambiguous answer.\n- **Objective**: The problem statement is objective and uses precise clinical and pharmacological terminology. There are no subjective or opinion-based elements.\n- **Completeness and Consistency**: The data provided (age, sex, weight, SCr) are sufficient for the Cockcroft-Gault calculation. The dosing rules are explicitly stated and are not contradictory.\n- **Realism**: The patient's vital statistics and clinical context are plausible for a general surgery inpatient. The serum creatinine value is within a range indicative of moderate renal impairment in an elderly individual, making the dose-adjustment question relevant.\n\nThe problem does not violate any of the invalidity criteria. It is a well-defined, scientifically sound, and clinically relevant calculation problem.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\n### Solution\nThe primary task is to determine the appropriate dose of enoxaparin by first estimating the patient's creatinine clearance ($\\text{CrCl}$) using the Cockcroft-Gault equation.\n\nThe Cockcroft-Gault formula for estimating $\\text{CrCl}$ in $\\mathrm{mL/min}$ is:\n$$ \\text{CrCl} = \\frac{(140 - \\text{Age}) \\times \\text{Weight}}{72 \\times \\text{SCr}} \\times C $$\nwhere Age is in years, Weight is in kilograms (kg), and serum creatinine (SCr) is in mg/dL. The constant $C$ is a sex-based correction factor, where $C=1$ for males and $C=0.85$ for females.\n\nThe given parameters for the patient are:\n- Age = $76$ years\n- Weight = $60$ kg\n- SCr = $1.6$ mg/dL\n- Sex = female, so the correction factor $C$ is $0.85$.\n\nWe substitute these values into the Cockcroft-Gault equation:\n$$ \\text{CrCl} = \\frac{(140 - 76) \\times 60}{72 \\times 1.6} \\times 0.85 $$\n\nFirst, we calculate the terms in the numerator and the denominator:\n- Numerator: $(140 - 76) \\times 60 = 64 \\times 60 = 3840$\n- Denominator: $72 \\times 1.6 = 115.2$\n\nNow, we perform the division and apply the correction factor for female sex:\n$$ \\text{CrCl} = \\frac{3840}{115.2} \\times 0.85 $$\n$$ \\text{CrCl} \\approx 33.333... \\times 0.85 $$\n$$ \\text{CrCl} \\approx 28.333... \\; \\mathrm{mL/min} $$\n\nThe estimated creatinine clearance is approximately $28.33$ $\\mathrm{mL/min}$.\n\nThe problem states the pharmacokinetic principle for enoxaparin dosing: a dose reduction is required when creatinine clearance is less than $30$ $\\mathrm{mL/min}$. Our calculated value, $\\text{CrCl} \\approx 28.33$ $\\mathrm{mL/min}$, satisfies this condition:\n$$ 28.33  30 $$\n\nAccording to the provided institutional standard, the enoxaparin dose should be reduced from $40$ mg to $30$ mg once daily when $\\text{CrCl}  30$ $\\mathrm{mL/min}$.\n\nTherefore, the appropriate once-daily enoxaparin prophylaxis dose for this patient is $30$ mg.", "answer": "$$\\boxed{30}$$", "id": "5199490"}, {"introduction": "Beyond dosing for an individual, an expert clinician must be able to critically appraise the evidence that underpins treatment guidelines. Measures such as Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) are essential tools for translating clinical trial data into meaningful practice. This exercise [@problem_id:5199422] provides hands-on practice in deriving these values from first principles, allowing you to quantify the real-world impact of an intervention like extended VTE prophylaxis and to better communicate treatment benefits and risks.", "problem": "A randomized cohort of $500$ adult patients undergoing major cancer surgery receives either in-hospital-only pharmacologic prophylaxis or extended post-discharge prophylaxis to day $30$. Assume the $30$-day symptomatic venous thromboembolism (VTE) risk with in-hospital-only prophylaxis is $0.06$, and the $30$-day risk with extended prophylaxis is $0.03$. Starting from the definition of absolute risk as the probability of an event per patient over the interval of interest, and interpreting expected event counts in a cohort of size $n$ as $n$ times the corresponding per-patient risk, derive from first principles:\n- the absolute risk reduction over $30$ days as the difference in event probabilities between strategies, and\n- the Number Needed to Treat (NNT), defined as the smallest integer number of patients to treat such that the expected number of VTE events prevented is at least one.\n\nCompute the absolute risk reduction as a unitless decimal and derive the conventional integer $NNT$ by taking the ceiling of the reciprocal of the absolute risk reduction. Do not round the absolute risk reduction. Report both values in the order absolute risk reduction, $NNT$.", "solution": "The problem has been validated and is determined to be sound. It is scientifically grounded in established principles of clinical epidemiology and biostatistics, well-posed with clear definitions and objectives, and free from internal contradictions or ambiguities. The data provided are plausible for the clinical scenario described. The problem falls squarely within the specified topic of venous thromboembolism prevention in surgical patients.\n\nLet $P_C$ represent the absolute risk, defined as the probability of a symptomatic venous thromboembolism (VTE) event over a $30$-day period, for a patient in the control group (in-hospital-only prophylaxis). From the problem statement, we have:\n$$P_C = 0.06$$\n\nLet $P_T$ represent the absolute risk of a VTE event over the same period for a patient in the treatment group (extended prophylaxis). From the problem statement, we have:\n$$P_T = 0.03$$\n\nThe problem statement asks for a derivation of the absolute risk reduction (ARR) from first principles, defining it as the difference in event probabilities between the two strategies. The reduction in risk afforded by the treatment is the risk in the control group minus the risk in the treatment group.\n$$ARR = P_C - P_T$$\nSubstituting the given numerical values:\n$$ARR = 0.06 - 0.03 = 0.03$$\nThis value is a unitless decimal, as required.\n\nNext, we must derive the Number Needed to Treat (NNT) from first principles. The problem defines NNT as the smallest integer number of patients to treat, let's denote this by the variable $N$, such that the expected number of VTE events prevented is at least one.\n\nThe problem specifies that the expected number of events in a cohort of size $n$ is calculated as $n$ times the per-patient risk. Let's consider a cohort of $N$ patients.\n\nIf this cohort of $N$ patients were to follow the control strategy, the expected number of VTE events, $E_C$, would be:\n$$E_C = N \\times P_C$$\n\nIf the same cohort of $N$ patients were to receive the extended prophylaxis (the treatment strategy), the expected number of VTE events, $E_T$, would be:\n$$E_T = N \\times P_T$$\n\nThe expected number of VTE events prevented by treating these $N$ patients is the difference between the expected events in the control scenario and the expected events in the treatment scenario.\n$$\\text{Expected Events Prevented} = E_C - E_T = (N \\times P_C) - (N \\times P_T)$$\nFactoring out $N$, we get:\n$$\\text{Expected Events Prevented} = N \\times (P_C - P_T)$$\nWe recognize the term $(P_C - P_T)$ as the absolute risk reduction, $ARR$.\n$$\\text{Expected Events Prevented} = N \\times ARR$$\n\nThe definition of NNT requires that this quantity be at least $1$. We can therefore establish the inequality:\n$$N \\times ARR \\ge 1$$\nTo find the value of $N$ that satisfies this condition, we solve for $N$:\n$$N \\ge \\frac{1}{ARR}$$\nSince NNT is defined as the *smallest integer* number of patients, $N$ must be the smallest integer that is greater than or equal to $\\frac{1}{ARR}$. This is precisely the definition of the ceiling function.\n$$NNT = \\left\\lceil \\frac{1}{ARR} \\right\\rceil$$\nThis derivation from first principles confirms the conventional calculation method provided in the problem statement.\n\nNow, we substitute the calculated value of $ARR = 0.03$ into this formula to compute the specific NNT for this scenario.\n$$NNT = \\left\\lceil \\frac{1}{0.03} \\right\\rceil$$\nCalculating the reciprocal:\n$$\\frac{1}{0.03} = \\frac{1}{3/100} = \\frac{100}{3} = 33.333...$$\nTaking the ceiling of this value:\n$$NNT = \\lceil 33.333... \\rceil = 34$$\nTherefore, the smallest integer number of patients that need to be treated with extended prophylaxis to prevent at least one VTE event is $34$.\n\nThe two requested values are the absolute risk reduction, $ARR = 0.03$, and the Number Needed to Treat, $NNT = 34$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.03  34\n\\end{pmatrix}\n}\n$$", "id": "5199422"}, {"introduction": "Textbook recommendations provide a foundation, but clinical expertise is demonstrated in managing complex cases where guidelines conflict. The decision to initiate VTE prophylaxis becomes most challenging when a patient's high risk of thrombosis is matched by an equally high risk of bleeding. This culminating practice problem [@problem_id:5199495] immerses you in such a scenario, requiring a nuanced assessment that integrates multiple contraindications—thrombocytopenia, active hemorrhage, renal failure, and neuraxial anesthesia. By navigating these competing dangers, you will practice the critical skill of balancing risks to arrive at the safest possible management strategy for a vulnerable surgical patient.", "problem": "A $68$-year-old patient is scheduled for open colorectal cancer resection and will receive a thoracic epidural catheter for postoperative analgesia. Preoperative laboratories reveal platelet count $55{,}000/\\mu\\mathrm{L}$ and creatinine clearance $25\\,\\mathrm{mL/min}$. The patient has melena and endoscopy confirms an actively bleeding gastric ulcer that has been treated endoscopically but still shows high-risk stigmata. The surgical team requests a plan for venous thromboembolism (VTE) prophylaxis.\n\nUsing first principles, reason from the following foundational bases:\n- Virchow’s triad: venous stasis, endothelial injury, and hypercoagulability as drivers of VTE risk, which is elevated after major abdominal cancer surgery due to operative trauma and postoperative immobility.\n- Determinants of bleeding risk: thrombocytopenia, active bleeding lesions, and procedural risk of neuraxial techniques with potential for spinal epidural hematoma.\n- Pharmacokinetic properties: low molecular weight heparin (LMWH) is renally cleared and accumulates when creatinine clearance is reduced, while unfractionated heparin (UFH) has shorter half-life, is not predominantly renally cleared, and is more readily reversible.\n- Neuraxial safety principles from regional anesthesia practice: the presence of an epidural catheter materially increases the clinical significance of any anticoagulation-associated bleeding, with thresholds for safe neuraxial management commonly requiring platelet counts closer to normal and strict timing around anticoagulant dosing to minimize spinal epidural hematoma risk.\n\nWhich of the following strategies best estimates this patient’s bleeding risk and most appropriately justifies withholding or modifying pharmacologic VTE prophylaxis?\n\nA. Proceed with standard LMWH prophylaxis using enoxaparin $40\\,\\mathrm{mg}$ subcutaneously once daily starting $12$ hours preoperatively, maintain the epidural catheter throughout the dosing period, and reassess after $48$ hours.\n\nB. Use dose-reduced LMWH because of renal impairment: enoxaparin $30\\,\\mathrm{mg}$ subcutaneously once daily starting $12$ hours postoperatively with the epidural catheter in place, ensuring catheter removal occurs $12$ hours after the last enoxaparin dose.\n\nC. Withhold pharmacologic prophylaxis initially due to high bleeding risk (platelet count $55{,}000/\\mu\\mathrm{L}$, active gastrointestinal ulcer, and planned epidural catheter); use intermittent pneumatic compression and early ambulation, and defer anticoagulant prophylaxis until the ulcer is controlled, platelets increase to a safer threshold (for example $75{,}000/\\mu\\mathrm{L}$) and the epidural catheter is removed; then initiate UFH $5{,}000$ units subcutaneously every $8$ to $12$ hours rather than LMWH given creatinine clearance $25\\,\\mathrm{mL/min}$.\n\nD. Place a temporary inferior vena cava (IVC) filter preoperatively to obviate the need for both mechanical and pharmacologic prophylaxis in the perioperative period.\n\nE. Start low-dose UFH $5{,}000$ units subcutaneously every $8$ hours immediately despite platelet count $55{,}000/\\mu\\mathrm{L}$ and planned epidural catheter placement, because UFH is reversible and not renally cleared, and continue the epidural uninterrupted.", "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\n- Patient age: $68$ years old.\n- Planned procedure: Open colorectal cancer resection with thoracic epidural catheter for postoperative analgesia.\n- Preoperative laboratory values:\n    - Platelet count: $55{,}000/\\mu\\mathrm{L}$.\n    - Creatinine clearance: $25\\,\\mathrm{mL/min}$.\n- Comorbidities/Active issues: Melena with endoscopically confirmed actively bleeding gastric ulcer, treated endoscopically but with remaining high-risk stigmata.\n- Task: Develop a plan for venous thromboembolism (VTE) prophylaxis.\n- Foundational Principles Provided:\n    1.  **Virchow’s triad**: Venous stasis, endothelial injury, and hypercoagulability drive VTE risk, which is high in major abdominal cancer surgery.\n    2.  **Bleeding risk determinants**: Thrombocytopenia, active bleeding lesions, and procedural risk of neuraxial techniques (spinal epidural hematoma).\n    3.  **Pharmacokinetic properties**: Low molecular weight heparin (LMWH) is renally cleared and accumulates with reduced creatinine clearance. Unfractionated heparin (UFH) is not predominantly renally cleared, has a shorter half-life, and is more readily reversible.\n    4.  **Neuraxial safety principles**: An indwelling epidural catheter elevates the risk associated with anticoagulation-induced bleeding. Safe neuraxial management requires higher platelet counts and strict timing of anticoagulant administration.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is well-grounded in established medical and pharmacological principles. Virchow's triad, the risks of anticoagulation, the pharmacokinetics of LMWH and UFH, and the safety guidelines for neuraxial anesthesia are all fundamental concepts in clinical medicine. The patient scenario is complex but medically plausible.\n- **Well-Posed**: The problem is well-posed. It presents a specific clinical case with sufficient data and asks for the best management strategy among a set of options, based on a provided framework of principles. A logical and superior solution can be deduced.\n- **Objective**: The problem statement is objective, providing concrete clinical data ($55{,}000/\\mu\\mathrm{L}$ platelets, $25\\,\\mathrm{mL/min}$ CrCl) and avoiding subjective language.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is a well-constructed clinical reasoning problem that requires the integration of multiple pathophysiological and pharmacological principles. The solution process may proceed.\n\n**Derivation of the Optimal Strategy**\n\nThe core of this problem is to balance a high risk of VTE against an extremely high risk of bleeding.\n\n1.  **VTE Risk Assessment**: Based on the principle of Virchow's triad, this patient has a high risk for VTE.\n    -   **Endothelial injury**: Major open abdominal surgery (colorectal resection) causes significant vessel wall trauma.\n    -   **Venous stasis**: Postoperative immobility is expected.\n    -   **Hypercoagulability**: Malignancy (cancer) is a well-known hypercoagulable state.\n    -   Conclusion: VTE prophylaxis is strongly indicated.\n\n2.  **Bleeding Risk Assessment**: The patient's bleeding risk is exceptionally high and immediate, due to a confluence of factors.\n    -   **Thrombocytopenia**: A platelet count of $55{,}000/\\mu\\mathrm{L}$ is significantly low (thrombocytopenia). Normal range is typically $150{,}000 - 450{,}000/\\mu\\mathrm{L}$. This level of thrombocytopenia is a major independent risk factor for bleeding.\n    -   **Active Bleeding Lesion**: The patient has an actively bleeding gastric ulcer with high-risk stigmata. This is a life-threatening condition in itself, and any form of anticoagulation could lead to catastrophic hemorrhage.\n    -   **Neuraxial Catheter**: An indwelling thoracic epidural catheter is planned. The combination of anticoagulation and/or thrombocytopenia in the presence of a neuraxial catheter creates a significant risk of spinal epidural hematoma, which can cause permanent paralysis. The provided neuraxial safety principles correctly state that the presence of the catheter elevates the clinical significance of any bleeding. Consensus guidelines (e.g., from the American Society of Regional Anesthesia and Pain Medicine, ASRA) consider a platelet count below $70{,}000 - 80{,}000/\\mu\\mathrm{L}$ a strong relative or absolute contraindication to placing or maintaining a neuraxial catheter, especially if anticoagulants are to be administered.\n    -   Conclusion: The cumulative risk of bleeding (gastrointestinal and neuraxial) is extremely high and outweighs the risk of VTE in the immediate perioperative period.\n\n3.  **Pharmacologic Agent Selection**: The choice of anticoagulant must account for the patient's renal function.\n    -   The patient has severe renal impairment, with a creatinine clearance of $25\\,\\mathrm{mL/min}$.\n    -   As per the provided pharmacokinetic principles, LMWH is cleared by the kidneys. It would accumulate in this patient, leading to an unpredictable and prolonged anticoagulant effect, further increasing the already high bleeding risk. Therefore, LMWH is a poor choice.\n    -   UFH is not significantly cleared by the kidneys. It has a short half-life and its effect can be fully and rapidly reversed with protamine sulfate. This makes UFH the preferred agent for this patient *if and when* pharmacologic prophylaxis is deemed safe to initiate.\n\n**Synthesis and Optimal Plan**\nThe analysis dictates a strategy that prioritizes mitigating the immediate, life-threatening bleeding risk. Pharmacologic anticoagulation is contraindicated at this moment. The only safe initial approach is to use non-pharmacologic methods for VTE prevention. Pharmacologic prophylaxis should be deferred until the major bleeding risks are resolved. When it is initiated, UFH should be the agent of choice.\n\n**Evaluation of Options**\n\n**A. Proceed with standard LMWH prophylaxis using enoxaparin $40\\,\\mathrm{mg}$ subcutaneously once daily starting $12$ hours preoperatively, maintain the epidural catheter throughout the dosing period, and reassess after $48$ hours.**\nThis option is fundamentally flawed. It ignores the severe renal impairment (LMWH would accumulate), the profound thrombocytopenia, the active GI bleed, and the catastrophic risk of spinal epidural hematoma from combining LMWH with an indwelling epidural catheter in a thrombocytopenic patient. Starting preoperatively is particularly reckless given the active ulcer.\n**Verdict: Incorrect.**\n\n**B. Use dose-reduced LMWH because of renal impairment: enoxaparin $30\\,\\mathrm{mg}$ subcutaneously once daily starting $12$ hours postoperatively with the epidural catheter in place, ensuring catheter removal occurs $12$ hours after the last enoxaparin dose.**\nThis option correctly adjusts the enoxaparin dose for renal failure ($CrCl  30\\,\\mathrm{mL/min}$). However, it fails to address the more critical issues. It still proposes using an anticoagulant in a patient with a platelet count of $55{,}000/\\mu\\mathrm{L}$, an active GI bleed, and an indwelling epidural catheter. The risk of major bleeding, especially spinal epidural hematoma, remains unacceptably high.\n**Verdict: Incorrect.**\n\n**C. Withhold pharmacologic prophylaxis initially due to high bleeding risk (platelet count $55{,}000/\\mu\\mathrm{L}$, active gastrointestinal ulcer, and planned epidural catheter); use intermittent pneumatic compression and early ambulation, and defer anticoagulant prophylaxis until the ulcer is controlled, platelets increase to a safer threshold (for example $75{,}000/\\mu\\mathrm{L}$) and the epidural catheter is removed; then initiate UFH $5{,}000$ units subcutaneously every $8$ to $12$ hours rather than LMWH given creatinine clearance $25\\,\\mathrm{mL/min}$.**\nThis option correctly identifies that the bleeding risk is prohibitive for immediate pharmacologic prophylaxis. It appropriately recommends initial management with mechanical prophylaxis (intermittent pneumatic compression, IPC) and early ambulation, which is the standard of care in this situation. It establishes clear, logical, and safe criteria for when to reconsider pharmacologic prophylaxis (control of bleed, platelet recovery, removal of epidural catheter). Finally, it correctly selects UFH as the preferred agent over LMWH due to the patient's severe renal impairment. This strategy systematically and correctly addresses every element of the problem based on the provided principles.\n**Verdict: Correct.**\n\n**D. Place a temporary inferior vena cava (IVC) filter preoperatively to obviate the need for both mechanical and pharmacologic prophylaxis in the perioperative period.**\nThis option reflects a misunderstanding of the indications for IVC filters. IVC filters are indicated for patients with *documented proximal DVT or PE* who have an absolute contraindication to therapeutic anticoagulation. They are not recommended for primary VTE prophylaxis. Furthermore, an IVC filter does not prevent the formation of DVTs in the lower extremities, so mechanical prophylaxis would still be necessary.\n**Verdict: Incorrect.**\n\n**E. Start low-dose UFH $5{,}000$ units subcutaneously every $8$ hours immediately despite platelet count $55{,}000/\\mu\\mathrm{L}$ and planned epidural catheter placement, because UFH is reversible and not renally cleared, and continue the epidural uninterrupted.**\nWhile this option correctly identifies UFH as the appropriate drug class for the renal failure, it proposes its immediate use in a context of extreme risk. Administering any anticoagulant to a patient with a platelet count of $55{,}000/\\mu\\mathrm{L}$ and an indwelling epidural catheter is a violation of neuraxial safety principles. The active GI bleed adds another absolute contraindication. The reversibility of UFH does not prevent a bleed from occurring, and a spinal epidural hematoma is a devastating event even if the anticoagulant effect can be reversed later. This approach is reckless.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{C}$$", "id": "5199495"}]}